FUNDAMENTALS · Fundamentals · CN Healthcare

HJ Science (6132) Fundamentals 2026 — Revenue Analysis | SniperIQ

HJ Science (6132) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK

.7B, trading at HK$49.60 on the HKSE. This SniperIQ fundamentals page covers HJ Science's valuation, profitability (net margin -1033.5%), revenue (HK
6M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
.7B
Net Margin-1033.5%
Revenue (FY25)HK
6M

Full research coverage

Frequently Asked Questions

What is HJ Science's market cap?

HJ Science (6132) has a market capitalization of approximately HK

.7B, trading at HK$49.60 on the HKSE. Market cap moves with the live share price.

What is HJ Science's P/E ratio?

HJ Science's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is HJ Science?

HJ Science runs a net profit margin of -1033.5%, a gross margin of 100.0%, and an operating margin of -959.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does HJ Science generate?

HJ Science reported revenue of HK

6M for fiscal year 2025, with net income of -HK
67M and earnings per share (EPS) of -2.83. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does HJ Science pay a dividend?

HJ Science does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is HJ Science financially healthy?

HJ Science carries a debt-to-equity ratio of 0.04x and a current ratio of 4.20x, with a market beta of -0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is HJ Science a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HJ Science (6132) the key facts are: market cap HK

.7B, revenue HK
6M, 52-week range 30.78-82. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track HJ Science's full fundamentals live

Get HJ Science's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.